Allspring Global Investments Trims Vertex Pharmaceuticals Stake

The investment firm reduced its holdings in the biotech company by 3.7% in Q4 2025.

Apr. 2, 2026 at 7:08am

Got story updates? Submit your updates here. ›

Allspring Global Investments Holdings LLC, a major investment firm, reduced its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 3.7% during the fourth quarter of 2025, according to a recent SEC filing. The firm now owns 122,210 shares of the pharmaceutical company's stock, valued at $55,255,000.

Why it matters

Vertex Pharmaceuticals is a leading biotech company focused on developing treatments for serious diseases like cystic fibrosis. Changes in institutional ownership can signal shifts in market sentiment and investor confidence around a company's prospects.

The details

Allspring Global Investments sold 4,653 shares of Vertex Pharmaceuticals stock during the fourth quarter. The firm now holds a $55.3 million position in the company, down from $57.4 million at the end of the prior quarter. Vertex Pharmaceuticals' stock price has fluctuated in recent months as the company navigates the competitive pharmaceutical landscape.

  • Allspring Global Investments reported the stake reduction in a 13F filing on April 2, 2026, covering the fourth quarter of 2025.

The players

Allspring Global Investments Holdings LLC

A major investment management firm that oversees over $600 billion in assets.

Vertex Pharmaceuticals Incorporated

A Boston-based biotechnology company focused on developing treatments for serious diseases like cystic fibrosis.

Got photos? Submit your photos here. ›

The takeaway

This filing highlights the shifting investment landscape around Vertex Pharmaceuticals as the company continues to advance its pipeline of innovative treatments. Institutional ownership changes can provide insights into broader market sentiment around a stock.